Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity (Tables)

v3.19.3
Stockholders' Equity (Tables)
9 Months Ended
Sep. 30, 2019
Stockholders' Equity Note [Abstract]  
Schedule of share-based compensation, stock options, activity
    Shares Underlying Options     Weighted Average Exercise Price     Weighted average Remaining Contractual Life (years)     Aggregate Intrinsic Value  
Outstanding at December 31, 2018     302,772     $ 18.30       7.20     $ -  
Granted     99,072       2.32               -  
Forfeited     (21,448 )     13.09               -  
Outstanding at September 30, 2019     380,396     $ 14.43       7.09     $ -  
Schedule of share-based compensation

   

Three Months ended

September 30,

   

Nine Months ended

September 30,

 
    2019     2018     2019     2018  
Research and development   $ 3,799     $ 2,127     $ 11,274     $ 8,837  
Selling, general and administrative     (53,862)       785,609       576,782       2,426,701  
Total   $ (50,063)     $ 787,736     $ 588,056     $ 2,435,538  

Schedule of share-based payment award, stock options, valuation assumptions
 

For the three and nine months ended

September 30,

  2019   2018
Fair value of common stock $ 2.32     $10.92 – $13.26
Expected volatility   151.76%     118.10% - 143.50%
Dividend yield $ -   $ -
Risk-free interest   2.70%     2.85% - 3.00%
Expected life (years)   5.5     5.125 - 5.33
Schedule of common stock warrant activity

    Number of Warrants     Weighted Average Exercise Price     Weighted Average Remaining Contractual Life (Years)  
Outstanding and exercisable at December 31, 2018     863,084     $ 6.00       2.51  
Exercised, K Warrants     (277,778 )     0.06       -  
Outstanding and exercisable at September 30, 2019     585,306     $ 8.85       2.95